Analysts think HRTX stock price could increase by 111%
May 07, 2025, 11:26 AM
-16.98%
What does HRTX do
Heron Therapeutics, based in San Diego, develops pharmaceutical products for acute care and oncology, including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, with 126 employees. Its products are distributed in the U.S.
4 analysts think HRTX stock price will increase by 111.18%. The current median analyst target is $5.10 compared to a current stock price of $2.42. The lowest analysts target is $4.04 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
